FiercePharma

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
PharmaTimes

EU approves AZ/B-MS first-in-class diabetes drug Forxiga

AstraZeneca and Bristol-Myers Squibb are celebrating following the approval of their diabetes drug Forxiga in the European Union. AstraZeneca and Bristol-Myers Squibb are celebrating following the ...
FiercePharma

Forxiga® receives regulatory approval in Japan for the treatment of type 2 diabetes

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
FierceBiotech

FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes

AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).
AOL

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in

PRINCETON, N.J. and LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and AstraZeneca (NYS: AZN) today announced that the European Commission has approved Forxiga ™ (dapagliflozin) ...
Business Wire

Forxiga™ (Dapagliflozin), erster SGLT-2-Hemmer der neuen Substanzklasse mit insulinunabhängiger Wirkung jetzt in der Europäischen Union zur Behandlung des Typ-2-Diabetes ...

PARIS und LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) und AstraZeneca (NYSE: AZN) gaben heute bekannt, dass die Europäische Kommission Forxiga™ (Dapagliflozin)-Tabletten für die ...
BioWorld

Astrazeneca to withdraw diabetes drug Forxiga from Korea

Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...
Pharmabiz

AstraZeneca’s Forxiga study shows reduced progression of kidney disease for type-2 diabetes

AstraZeneca has presented the data of Forxiga study which showed reduced progression of kidney disease for type-2 diabetes (T2D) at the American Diabetes Association (ADA) 79th Scientific Sessions, ...
Nasdaq

AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure

AstraZeneca PLC AZN announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval for its SGLT2 ...
The Motley Fool

Here's What This Label Expansion Means for AstraZeneca Investors

The EMA's approval of Forxiga for chronic kidney disease gives AstraZeneca access to millions of patients in the EU. Forxiga's efficacy and this massive potential market should help the label ...
Nasdaq

AstraZeneca: Forxiga Cardiovascular Outcomes Benefit Approved In China

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Wednesday that China's National Medical Products Administration or NMPA has approved Forxiga's (dapagliflozin) cardiovascular ...
Business Wire

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...